Open AccessSevere upper gastrointestinal disorders in pembrolizumab‐treated non‐small cell lung cancer patient
Author(s) -
Onuki Tsugitoshi,
Morita Eri,
Sakamoto Noritaka,
Nagai Yoshiaki,
Sata Masafumi,
Hagiwara Koichi
Publication year - 2018
Publication title -
respirology case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.304
H-Index - 9
ISSN - 2051-3380
DOI - 10.1002/rcr2.334
Subject(s) - pembrolizumab , medicine , adverse effect , lung cancer , immune system , duodenum , gastroenterology , stomach , cancer , jejunum , esophagus , lung , oncology , immunotherapy , immunology
Pembrolizumab is an immune checkpoint inhibitor that induces side effects called “immune‐related adverse events” (irAEs). Various types of organs are affected by irAEs, although reports of upper gastrointestinal disorders are rare. Here, we report a case of extensive inflammatory pathologies in the oesophagus, stomach, duodenum, and jejunum after the administration of pembrolizumab for non‐small cell lung cancer.